PRECLINICAL ASSETS MARKET ANALYSIS

Preclinical Assets Market, by Service ( Bioanalysis and DMPK studies (In vitro, In-vivo), Toxicology Testing (GLP, Non-GLP), compound management (Process R&D, Custom Synthesis, Asymmetric Synthesis & Others (Scale-up, cGMP, etc.), Safety Pharmacology, Others(Chemistry, etc.)), by Model type (Patient Derived Organoid (PDO) Model, Patient derived xenograft model), by End user (Biopharmaceutical Companies, Government Institutes & Others (Academic and Research institutes) ), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Nov 2022
Code : CMI5326
Pages :176
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

Global Preclinical Assets Market: Key Developments

In September 2021, Viroclinics-DDL, a global contract research organization, announced the launch of Viroclinics Xellerate, a newly formed Business Unit focused on clinical trial support and global logistics services.

On February 17, 2022, Viroclinics-DDL, a global contract research organization, announced that Cerba Research, the group’s global clinical trial central and specialty laboratory services division, had merged with Viroclinics-DDL, a global specialist virology and immunology contract research organization (CRO). This merger will help the company in further expanding and transforming diagnostic solutions for clinical trials

In November 2019, Envigo RMS LLC, a global supplier of research models and associated services, announced an agreement to acquire the assets of the research models business unit of Horizon Discovery Group plc., a research company. This acquisition will help the company in further expansion of the services in clinical research.

Preclinical Assets Market Report Snapshots